AIM ImmunoTech
Tracked across 2 events · 16 articles · First seen Feb 11, 2026 · Last active Jun 08, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
Impact: AIM ImmunoTech conducted a rights offering to raise capital, which resulted in approximately $1.8 million in subscriptions, significantly less than the initially expected $12 million, indicating a shortfall in fundraising.
Feb 11, 2026 · 6 articles
Tech
AIM ImmunoTech Inc. reported positive mid-year interim clinical progress from its Phase 2 DURIPANC study, evaluating Ampligen (rintatolimod) in combination with AstraZeneca's Imfinzi (durvalumab) for metastatic pancreatic cancer. The company also announced the ahead-of-schedule enrollment…
Impact: AIM ImmunoTech Inc. is the developer of Ampligen and is reporting positive interim results from its Phase 2 DURIPANC study, which could lead to significant value inflection for the company.
Jun 01, 2026 · 10 articles
95
AIM ImmunoTech reported positive progressAIM ImmunoTech reports...
85
AIM ImmunoTech announced enrollmentAIM ImmunoTech reports...
80
AIM ImmunoTech planning Phase 3 trialAIM ImmunoTech reports...
70
AIM ImmunoTech collaborated AstraZenecaAIM ImmunoTech reports...
NEWSDESK
Track AIM ImmunoTech live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard